Lavinia Vija
Research Interests
Lavinia Vija has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chloé Lamesa
Radiopharmacy Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, CEDEX 09, 31059 Toulouse, France
1 shared publication - Delphine Vallot
Oncopole Claudius Regaud, Toulouse, France
1 shared publication - Frederic Courbon
Nuclear Medicine Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, CEDEX 09, 31059 Toulouse, France
1 shared publication - Jean-Pierre Delord
Medical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, CEDEX 09, 31059 Toulouse, France
1 shared publication - Jean-Sébastien Texier
Nuclear Medicine Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, CEDEX 09, 31059 Toulouse, France
1 shared publication - Marie Terroir-Cassou-Mounat
Department of Nuclear Medicine, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, CEDEX 09, 31059, France.
1 shared publication
Latest Publications
- Open Access
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11586
Special Issue “Molecular Biology of the Thyroid Cancer and Thyroid Dysfunctions”
Thyroid disorders (comprising thyroid dysfunctions such as hypo- or hyperthyroidism and thyroid cancer) are among the most common endocrine pathologies
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11586
Open AccessSpecial Issue “Molecular Biology of the Thyroid Cancer and Thyroid Dysfunctions”
Thyroid disorders (comprising thyroid dysfunctions such as hypo- or hyperthyroidism and thyroid cancer) are among the most common endocrine pathologies
- Open Access
- 16 May 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (5) , 754
RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [177Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [177Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [177Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [68Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [177Lu]Lu-PSMA-617 in salivary gland cancer.
- 16 May 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (5) , 754
Open AccessRadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [177Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [177Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [177Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [68Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [177Lu]Lu-PSMA-617 in salivary gland cancer.